Reading a Device Clinical Claim: '510(k) Cleared For' vs What the Rep Is Implying It Does

Cleared is not approved, and the words are doing work

Most aesthetic energy devices reach the market through the 510(k) pathway, in which the manufacturer demonstrates the device is substantially equivalent to an already-marketed device for a defined intended use. That's a meaningful regulatory step — but it is a clearance based on equivalence, not the rigorous premarket approval process some drugs and high-risk devices undergo. When a rep says "FDA cleared" quickly and lets your brain hear "FDA approved," that elision is the whole pitch. The words mean different things, and the difference matters because your marketing will be judged against the precise one.

An indication is not a marketing license

Every cleared device has a specific cleared indication — the defined use the clearance actually covers. That indication is narrower, often much narrower, than the universe of outcomes a rep will gesture at across a lunch. A device cleared for one specific application is not thereby blessed to be advertised for every adjacent benefit a patient might want, and the clearance certainly doesn't authorize drug-style efficacy claims about results.

The trap is subtle because the rep rarely tells you to break a rule. They show before-and-afters, mention what "providers are seeing," and let you build the marketing claim yourself — at which point it's your ad, your practice's name, and your liability, not theirs.

Your advertising inherits the device's regulatory reality

This is the part owners miss: clinicians often have latitude in how they use a device, but your advertising is held to a different and stricter standard. Promote a device for uses beyond its cleared indication, or imply efficacy the clearance doesn't support, and you've created an advertising claim that the FTC and your state board can scrutinize — independent of anything the rep said and regardless of how common the claim is in your market. "Everyone advertises it that way" is not a defense; it's a description of shared exposure.

Read the paperwork, not the rep

The cleared indication is a matter of record. Before you build a single ad around a new platform:

• Ask the manufacturer for the specific cleared indications in writing, and read them against what you intend to claim.
• Treat every verbal benefit as marketing until the documentation confirms it. If the rep won't put a claim in writing, you certainly shouldn't put it in an ad.
• Separate how your clinicians may use the device from how you may advertise it. The first is a clinical judgment; the second is an advertising-law question with a narrower answer.

What to do

• Get cleared indications in writing for every device before marketing it, and align your claims to that language, not the demo.
• Train your marketing team and any agency that the device's clearance — not the rep's enthusiasm — defines what you can claim.
• Avoid drug-style efficacy language ("eliminates," "guaranteed results") that a clearance doesn't support, and apply the same discipline to influencer and social posts about the device.
• When in doubt, run the claim past counsel. A reviewed ad is cheaper than a board inquiry.

The device is probably excellent; that's not the issue. The issue is that the rep is paid to blur a regulatory line that you, not they, will be standing on when a regulator or a competitor reads your advertising. Read the clearance, claim only what it supports, and the device is an asset. Believe the lunch, and you've turned a good machine into an advertising liability with your name on it.